Jasper Therapeutics — Third Quarter 2026 Earnings Summary
Financial Performance:
- Revenue for the three months ended September 30, 2026, was $8.0 million, compared to $0 in the same period in 2025.
- Research and development expense for the quarter was $8.3 million, down from $14.4 million in the prior year period; for the nine months ended September 30, 2026, R&D expense was $19.3 million compared to $51.7 million in 2025.
- General and administrative expense for the quarter was $6.4 million, up from $4.8 million in the prior year period; for the nine months ended September 30, 2026, G&A expense was $15.6 million compared to $16.3 million in 2025.
- Acquired in-process research and development expense of $129.5 million was recorded in the quarter and nine-month period due to the Kira Pharmaceuticals acquisition.
- Total operating expenses for the quarter were $152.2 million, compared to $19.2 million in the prior year period; for the nine months ended September 30, 2026, total operating expenses were $172.3 million compared to $68.0 million in 2025.
- Net loss for the three months ended September 30, 2026, was $144.5 million, compared to $18.7 million in the prior year period; for the nine months ended September 30, 2026, net loss was $148.4 million compared to $66.7 million in 2025.
- Net loss per share attributable to common stockholders was $10.19 for the quarter and $14.31 for the nine months ended September 30, 2026.
- Cash and cash equivalents as of September 30, 2026, totaled $135.3 million, an increase from $28.7 million as of December 31, 2025.
- Total assets as of September 30, 2026, were $147.4 million, compared to $35.8 million as of December 31, 2025.
- Total liabilities as of September 30, 2026, were $20.9 million, compared to $31.6 million as of December 31, 2025.
- Non-voting redeemable convertible preferred stock was valued at $263.5 million as of September 30, 2026.
- Stockholders' equity was a deficit of $140.2 million as of September 30, 2026, compared to positive equity of $4.2 million as of December 31, 2025.
Guidance and Future Outlook:
- Interim data from the IgAN cohort of the renal basket study is expected to be reported in the fourth quarter of 2026.
- Updated data from the renal basket study is expected in the first quarter of 2027.
- The first patient in the expansion cohort for focal segmental glomerulosclerosis (FSGS) is expected to be dosed in the first quarter of 2027.
- Initial data from the Phase 1/2 case control study evaluating briquilimab as a conditioning agent for SCID patients is expected to be presented in the fourth quarter of 2026.
- Management anticipates presenting additional updates from pipeline programs in 2027.
Business Segments and Product Lines:
- Completed enrollment in the first cohort of the Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).
- Commenced patient enrollment in the C3 glomerulopathy (C3G)/IC-MPGN cohort of the renal basket study, with the first IC-MPGN patient dosed.
- Announced the opening of an expansion cohort in the renal basket study for patients with FSGS.
- Completing a Phase 1/2 case control study evaluating briquilimab as a conditioning agent for SCID patients receiving hematopoietic stem cell transplant.
- KP701, a dual-acting anti-CD79BxCD32B monoclonal antibody, is advancing to the clinic.
- Vensobafusp alfa is a dual-complement inhibitor currently under evaluation in nephrology disorders following positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH).
- Briquilimab is an anti-KIT antibody demonstrating positive clinical results for stem cell transplant conditioning in SCID, Fanconi anemia, and mast cell-mediated diseases.
Market and Competitive Landscape:
- No specific market share, competitor names, or market trend data was provided in the press release.
Risks and Challenges:
- Risks include the market price of common stock relative to the exchange ratio in connection with the merger, unexpected costs from the merger, and potential adverse reactions to business relationships resulting from the Kira acquisition.
- Uncertainties exist regarding product candidates, clinical development timelines, regulatory approvals, and the ability to obtain sufficient additional capital.
- Risks include the failure to realize value from product candidates, the failure to realize anticipated benefits of the Kira acquisition, and the possibility that stockholders may not approve the conversion of preferred stock.
- Risks include the ability to maintain the listing of common stock on the Nasdaq Capital Market.
Management Commentary and Tone:
- Jeet Mahal, President and CEO, stated the company has made progress advancing development programs following the acquisition of Kira Pharmaceuticals.
- Management believes the bifunctional ability of vensobafusp alfa to inhibit both alternative and terminal complement pathways may provide differentiated onset and efficacy in complement-driven diseases.
- The tone is forward-looking, emphasizing the completion of enrollment and the expectation of data readouts in late 2026 and early 2027.
Other Key Points:
- In July 2026, Jasper completed the acquisition of Kira Pharmaceuticals in an all-stock transaction.
- Concurrent with the Kira acquisition, Jasper entered into a private placement for non-voting convertible preferred stock, closing on July 20, 2026, with gross proceeds of approximately $132.0 million.
- In November 2026, the company effected a 1-for-30 reverse stock split, resulting in approximately 1.1 million shares of common stock issued and outstanding.
- The company commenced an offer to purchase outstanding warrants issued in its September 18, 2025 underwritten public offering at a price of $9.72 per warrant; 283,689 warrants were tendered for an aggregate payment of approximately $2.8 million, leaving 127,834 warrants outstanding.
- Appointments made include Lisa Pitt as Senior Vice President, Regulatory Affairs, and Shiguang Liu as Vice President, Clinical Development.
- Company
- JASPER THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Biotechnology